These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 9636630)
21. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation. Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548 [No Abstract] [Full Text] [Related]
22. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients. Kumano K; Irie A; Mashimo S; Endo T; Koshiba K Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691 [No Abstract] [Full Text] [Related]
23. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation. Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571 [No Abstract] [Full Text] [Related]
27. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494 [No Abstract] [Full Text] [Related]
28. Increased expression of ICAM-1 and VCAM-1 in the skin after administration of the first dose of OKT3. ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Pals ST Transplant Proc; 1997; 29(1-2):325-7. PubMed ID: 9123022 [No Abstract] [Full Text] [Related]
29. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation. VanderWerf BA Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172 [No Abstract] [Full Text] [Related]
30. Prevention and treatment of rejection after simultaneous pancreas-kidney transplantation. Yang L; Liu YF; Liu SR; Wu G; Zhang JL; Meng YM; Shong SW; Li GC Chin Med Sci J; 2005 Sep; 20(3):210-3. PubMed ID: 16261897 [TBL] [Abstract][Full Text] [Related]
32. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens. Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684 [No Abstract] [Full Text] [Related]
33. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K; Munn SR; Sterioff S Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964 [No Abstract] [Full Text] [Related]
34. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. Burke GW; Ricordi C; Karatzas T; Carreno M; Markou M; Cirocco R; Ciancio G; Qian T; Selvaggi G; Alejandro R; Skyler JS; Roth D; Tzakis A; Miller J Transplant Proc; 1997; 29(1-2):1207-8. PubMed ID: 9123275 [No Abstract] [Full Text] [Related]
35. [OKT3 treatment of refractory renal allograft rejection]. Xu J; Ma J; Bai X Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection. Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306 [TBL] [Abstract][Full Text] [Related]
37. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. Kumar MS; Cahill K; Kumar AM; Panigrahi D; Seirka D; Singleton R; al-Abdullah IH; Laskow DA Transplant Proc; 1998 Jun; 30(4):1351-2. PubMed ID: 9636549 [No Abstract] [Full Text] [Related]
38. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. Chowdhury S; Kode RK; Ranganna K; Damask AM; Lam A; Fyfe B; Stabler S; Kumar AM; Tomeny MB; Kumar MS; Pankewycz O Transplant Proc; 2001; 33(1-2):1057-8. PubMed ID: 11267189 [No Abstract] [Full Text] [Related]
39. OKT3 versus methylprednisolone for primary treatment of rejection: a retrospective evaluation. Meijer RT; Keur I; Surachno S; ten Berge IJ; Schellekens PT Transplant Proc; 2001 May; 33(3):2196-7. PubMed ID: 11377501 [No Abstract] [Full Text] [Related]
40. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect. Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]